The central focus of Project 0019 is to correlate clinical observations with laboratory results to generate hypotheses regarding tumor progression or response to therapy, and to test these new hypotheses in the clinic. Clinical observations will result from studies focused on select hematologic malignancies and breast cancer. Patterns of tumor progression and treatment failure will serve to guide the laboratory cores and projects to produce new approaches to overcoming drug resistance using novel drugs, chemosensitizers, or changes in drug schedule or dosing.
The specific aims of project are: 1. To present clinical observations as hypotheses for laboratory investigations and refinements of laboratory directions; 2. To develop new therapeutic approaches for select hematologic malignancies and breast cancer using leads developed in the laboratory; 3. To study the biology and scientifically based new therapy of cancers by interrelating clinical observations and treatment outcome with pharmacokinetics, in vivo and in vitro models for drug development, and the investigation of drug resistance; 4. To test hypotheses generated by investigators of laboratory projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA017094-18A1
Application #
3749209
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797

Showing the most recent 10 out of 314 publications